Online citations, reference lists, and bibliographies.
← Back to Search

Hepatitis B Surface Antigen Nanoparticles Coated With Chitosan And Trimethyl Chitosan: Impact Of Formulation On Physicochemical And Immunological Characteristics.

M. Tafaghodi, V. Saluja, G. Kersten, H. Kraan, B. Slütter, Jean-Pierre Amorij, W. Jiskoot
Published 2012 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Mucosal immunization offers various advantages over parenteral vaccination, but typically requires potent delivery systems and/or adjuvants to result in protective immunity. Here we report on the preparation of trimethylated chitosan (TMC) and chitosan (CHT) nanoparticles (NPs) loaded with hepatitis B surface antigen (HB), by a simple and scalable method. TMC:HB and CHT:HB NPs were prepared by direct coating of antigen by polymer. The impact of buffer, pH and tonicity of the dispersion medium on NPs' polydispersity, zeta potential and association percentage of polymer with antigen was evaluated. Moreover, biological properties of both NPs were addressed in vitro by studying their effect on cell viability, transepithelial electrical resistance (TEER) and dendritic cell (DC) maturation. Finally, immunogenicity was assessed by evaluating IgG, IgG1, IgG2a, IgA titers and sIgA after both mucosal (nasal) as well intramuscular (i.m.) vaccination in a murine model. TMC:HB and CHT:HB NPs, prepared in acetate buffer pH 6.7 of three different tonicities, had comparable size, polydispersity, zeta potential and association percentage. TMC:HB NPs, but not CHT:HB NPs, had a mild negative effect on cell viability and TEER, and a considerable positive effect on DC maturation. After nasal and i.m. immunization, TMC:HB NPs in hypotonic medium and CHT:HB NPs in all media induced higher serum and nasal antibody titers compared with HB solution (P<0.001). After i.m. injection, both TMC:HB and CHT:HB NPs induced higher IgG and IgG2a titers compared with alum adsorbed HB (P<0.001). For CHT:HB NPs, the tonicity of the dispersion medium did not affect the mucosal and systemic immune responses. In conclusion, TMC NPs and CHT NPs are similarly potent mucosal immunoadjuvants for HB. Moreover, both polymers are potent immunoadjuvants for i.m. administered isotonic HB, resulting in higher IgG2a/IgG1 ratios compared with alum adjuvanted HB.
This paper references
10.1016/j.jconrel.2009.11.018
Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
S. Bal (2010)
10.1016/S0169-409X(01)00171-5
Chitosan as a novel nasal delivery system for vaccines.
L. Illum (2001)
10.1038/labinvest.2008.86
Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis
E. Ragnarsson (2008)
10.1016/J.JCONREL.2005.11.014
Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
M. Amidi (2006)
10.1016/j.ijpharm.2007.11.052
Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods.
A. Sadeghi (2008)
10.1016/S1473-3099(10)70157-2
Needle-free influenza vaccination.
Jean-Pierre Amorij (2010)
Relevance of the colloidal stability of chitosan / PLGA nanoparticles on their cytotoxicity profile
N Nafee (2009)
10.1007/s11095-009-9845-y
Physicochemical and Immunological Characterization of N,N,N-Trimethyl Chitosan-Coated Whole Inactivated Influenza Virus Vaccine for Intranasal Administration
N. Hagenaars (2009)
10.1016/J.VACCINE.2007.01.111
Vaccine adjuvants revisited.
J. Aguilar (2007)
Mucosal immunization with antigen - containing microparticles
AJ Almeida
10.1152/AJPCELL.2001.281.2.C388
Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers.
C. J. Watson (2001)
10.1016/j.ejpb.2008.03.004
Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.
A. Sadeghi (2008)
10.1002/JPS.2600760905
Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. II: Histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity.
T. Ohwaki (1987)
10.1016/j.jconrel.2009.08.018
Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
N. Hagenaars (2009)
10.1586/14760584.4.2.185
Nanoparticles as carriers for nasal vaccine delivery
M. Köping-Höggård (2005)
10.1016/j.jconrel.2009.05.011
Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
B. Slütter (2009)
10.1016/j.vaccine.2010.06.121
Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
B. Slütter (2010)
10.1016/j.biomaterials.2008.05.026
Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan.
R. Verheul (2008)
10.1016/j.biomaterials.2009.03.013
Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans.
R. Verheul (2009)
10.4049/jimmunol.168.4.1704
Microbial Compounds Selectively Induce Th1 Cell-Promoting or Th2 Cell-Promoting Dendritic Cells In Vitro with Diverse Th Cell-Polarizing Signals1
E. D. de Jong (2002)
10.1002/JPS.20718
Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?
L. Illum (2007)
10.1016/j.ijpharm.2009.04.049
Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile.
N. Nafee (2009)
10.1016/J.EJPB.2006.07.016
Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models.
G. Sandri (2007)
10.1016/j.jconrel.2010.01.027
Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine.
N. Hagenaars (2010)
10.1016/S0169-409X(01)00149-1
Exploiting M cells for drug and vaccine delivery.
M. A. Clark (2001)
10.1016/0022-1759(83)90303-4
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
T. Mosmann (1983)
10.1016/j.colsurfb.2009.07.024
Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits.
Mohamadreza Amin (2009)
10.1038/86373
Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria
M. Rescigno (2001)
10.1166/JNN.2010.2211
Preparation of N-trimethyl chitosan-protein nanoparticles intended for vaccine delivery.
Xing Yi Li (2010)
10.1016/j.jconrel.2010.09.018
Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
S. Bal (2010)
10.1016/j.jcis.2010.01.038
Synthesis and cytotoxicity assessment of superparamagnetic iron-gold core-shell nanoparticles coated with polyglycerol.
T. Jafari (2010)
10.3109/10611860903434035
Preparation and in vivo study of dry powder microspheres for nasal immunization
M. Tafaghodi (2010)
10.1080/10611860701637966
Rational design of nasal vaccines.
B. Slütter (2008)
10.1016/j.vaccine.2011.04.112
Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
S. Mangal (2011)
10.1081/DDC-120016684
Evaluation of the Mucoadhesive Properties of N-Trimethyl Chitosan Chloride
D. Snyman (2003)
10.1016/J.JCONREL.2007.05.025
Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration.
Worawan Boonyo (2007)
10.1016/j.ejps.2009.08.010
TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
B. Sayin (2009)
10.1002/JPS.2600740511
Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats.
T. Ohwaki (1985)
10.1016/j.jconrel.2010.06.028
Bioneedles as alternative delivery system for hepatitis B vaccine.
H. Hirschberg (2010)
10.2174/156720108783954833
Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid.
M. Tafaghodi (2008)
10.1016/j.ijpharm.2009.07.001
Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers.
A. Hafner (2009)
10.1016/j.addr.2009.11.009
Chitosan-based delivery systems for protein therapeutics and antigens.
M. Amidi (2010)
10.1016/S0264-410X(02)00686-2
Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice.
I. M. van der Lubben (2003)
10.1042/CS1000327
Comparison of nasal pH values in black and white individuals with normal and high blood pressure.
N. Ireson (2001)
10.1021/bm800276d
Why is chitosan mucoadhesive?
Ioannis A Sogias (2008)
10.1016/J.VACCINE.2006.06.086
N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
M. Amidi (2007)
10.1208/s12248-009-9168-2
Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant
V. Saluja (2009)
10.1016/j.jconrel.2010.06.009
Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
B. Slütter (2010)
10.1016/J.CARRES.2006.10.012
Increased sensitivity of chitosan determination by a dye binding method.
C. Wischke (2006)



This paper is referenced by
10.1007/978-3-319-41926-8_3
Chitosan Based Nanomaterials and Its Applications
Saurabh Bhatia (2016)
10.2217/nnm-2017-0015
Recent developments in nanocarrier-aided mucosal vaccination.
Olga Kammona (2017)
10.1016/j.ijpharm.2014.07.005
Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes.
Chompoonuch Sawaengsak (2014)
10.1371/journal.ppat.1003001
Vaccines: From Empirical Development to Rational Design
C. Rueckert (2012)
10.1016/j.micpath.2016.05.012
Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46.
M. Amirnasr (2016)
10.1142/9789814520652_0007
Polysaccharide-Based Nanocarriers for Drug Delivery
Carmen Teijeiro (2014)
10.15406/IJVV.2015.01.00007
Nanotechnology, Drug Delivery Systems and their Potential Applications in Hepatitis B Vaccine
Priscila Ferreira Perazzo (2015)
10.1007/978-981-13-0950-2_16
Biodegradable Polymeric Nanocarrier-Based Immunotherapy in Hepatitis Vaccination.
Seo Jin Hong (2018)
10.1016/j.ajps.2018.04.005
Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization
J. Mosafer (2019)
10.3109/02652048.2015.1073392
Development of chitosan–pullulan composite nanoparticles for nasal delivery of vaccines: optimisation and cellular studies
E. Cevher (2015)
10.3109/10837450.2013.784335
Foot and Mouth Disease virus-loaded fungal chitosan nanoparticles for intranasal administration: impact of formulation on physicochemical and immunological characteristics
Farzaneh Tajdini (2014)
10.11606/D.9.2012.TDE-15032013-163603
Nanopartículas de quitosana como veículo de vacinação contra a hepatite B via nasal
Jony Takao Yoshida (2012)
10.22034/IJI.2018.39397
Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
Mansure Hojatizade (2018)
10.7508/NMJ.2014.03.004
IN VIVO EVALUATION OF MUCOADHESIVE PROPERTIES OF NANOLIPOSOMAL FORMULATIONS UPON COATING WITH TRIMETHYLCHITOSAN POLYMER
B. Khameneh (2014)
10.3389/fimmu.2018.00562
Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax
A. Malik (2018)
10.1016/j.biotechadv.2014.12.004
Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.
R. Sharma (2015)
10.1111/1348-0421.12497
EDIII‐DENV3 nanospheres drive immature dendritic cells into a mature phenotype in an in vitro model
Nattika Nantachit (2017)
10.3389/fimmu.2018.02986
Mesenteric CD103+DCs Initiate Switched Coxsackievirus B3 VP1-Specific IgA Response to Intranasal Chitosan-DNA Vaccine Through Secreting BAFF/IL-6 and Promoting Th17/Tfh Differentiation
Haoxin Zhao (2018)
10.3109/02652048.2013.858791
Preparation and in vitro evaluation of surface-modified poly (lactide-co-glycolide) microparticles as biodegradable drug carriers for pulmonary peptide and protein delivery
B. Devrim (2014)
10.1016/j.carbpol.2016.10.041
N,N,N-Trimethyl chitosan: An advanced polymer with myriad of opportunities in nanomedicine.
A. Kulkarni (2017)
10.1021/mp4005029
Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.
Pamela T Wong (2014)
10.5582/ddt.2015.01025
Polysaccharides: Candidates of promising vaccine adjuvants.
Pingli Li (2015)
10.1016/j.carbpol.2020.116041
Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: In vitro and in vivo efficacy in comparison to CpG.
Meng-Hung Tsai (2020)
10.1039/C6RA14419E
The mechanism of action of acid-soluble chitosan as an adjuvant in the formulation of nasally administered vaccine against HBV
Z. Wang (2016)
10.1016/J.JDDST.2019.05.052
Streptomycin sulfate dry powder inhalers for the new tuberculosis treatment schedule
Farideh Shiehzadeh (2019)
Nano-adjuvanted polio vaccine: Preparation and characterization of chitosan and trimethylchitosan (TMC) nanoparticles loaded with inactivated polio virus and coated with sodium alginate
M. Tafaghodi (2014)
10.1016/J.JDDST.2015.08.010
Multi-enveloping of particulated antigens with biopolymers and immunostimulant polynucleotides
Jorge F. Correia-Pinto (2015)
Porous maltodextrin nanoparticles for the intranasal delivery of vaccines
B. Bernocchi (2016)
10.1016/B978-0-08-102985-5.00025-5
Nanoparticles for mucosal vaccine delivery
Aneesh Thakur (2020)
Highly versatile immunostimulating nanocapsules for specific immune
Sara Vicente (2014)
10.1016/j.bios.2015.11.007
Femtomolar level detection of RASSF1A tumor suppressor gene methylation by electrochemical nano-genosensor based on Fe3O4/TMC/Au nanocomposite and PT-modified electrode.
M. Daneshpour (2016)
10.2147/IJN.S165876
Novel application of trimethyl chitosan as an adjuvant in vaccine delivery
A. Malik (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar